rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
3
|
pubmed:dateCreated |
1990-2-13
|
pubmed:abstractText |
A novel 6-substituted acyclouridine derivative, 1-[(2-hydroxy-ethoxy) methyl]-6-phenylthiothymine (HEPT), has proved to be a potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1) in vitro. HEPT inhibits HIV-1 replication in various T4 cell cultures as well as peripheral blood lymphocytes and macrophages. The 50% antiviral effective concentration for HIV-1 (HTLV-IIIB) in MT-4 cells is 7.0 microM, while the 50% cytotoxic concentration for mock-infected MT-4 cells is 740 microM. Although HEPT is inhibitory to various strains of HIV-1, it has no effect on the replication of other retroviruses including HIV type 2. In contrast with the dideoxynucleoside (i.e. azidothymidine) 5'-triphosphates, the triphosphate of HEPT does not interact with HIV-1 reverse transcriptase. The mechanism of action of HEPT remains subject of further study.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0006-291X
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
29
|
pubmed:volume |
165
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1375-81
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2575380-Antiviral Agents,
pubmed-meshheading:2575380-CD4-Positive T-Lymphocytes,
pubmed-meshheading:2575380-Cell Line,
pubmed-meshheading:2575380-Cytopathogenic Effect, Viral,
pubmed-meshheading:2575380-Dose-Response Relationship, Drug,
pubmed-meshheading:2575380-HIV Antigens,
pubmed-meshheading:2575380-HIV-1,
pubmed-meshheading:2575380-HIV-2,
pubmed-meshheading:2575380-Lymphocytes,
pubmed-meshheading:2575380-Macrophages,
pubmed-meshheading:2575380-Thymine,
pubmed-meshheading:2575380-Virus Replication,
pubmed-meshheading:2575380-Zalcitabine,
pubmed-meshheading:2575380-Zidovudine
|
pubmed:year |
1989
|
pubmed:articleTitle |
Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative.
|
pubmed:affiliation |
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|